Good evening, this is Markets Desk with your end-of-day briefing.
Eli Lilly is giving investors fresh conviction tonight. Detailed Phase three results from the TRIUMPH-two trial show Retatrutide delivered significant weight loss and meaningful reductions in blood sugar levels for adults with obesity and type two diabetes. That triple-receptor agonist continues to look like Lilly's next major commercial catalyst, reinforcing the company's dominant position in the GLP-one space.
Shifting to geopolitical risk, Russia confirmed the crash of a Tu-ninety-five nuclear-capable bomber during a training exercise in its eastern region, killing at least six crew members. The aircraft is the backbone of Russia's long-range nuclear deterrent and critically, it is no longer in production, meaning this loss is genuinely irreplaceable and represents a measurable degradation of strategic capability.
And from the White House, President Trump signed an executive order renaming artificial intelligence to so-called super intelligence, calling the original term ineloquent and fake-sounding. Beyond the branding, the order signals a continued pivot away from AI safety frameworks established under the prior administration, with real downstream implications for how federal agencies regulate and procure AI systems going forward.
That's the tape. Markets Desk, signing off the floor.
